Cargando…

Effects of Purified Anthocyanins in People at Risk for Dementia: Study Protocol for a Phase II Randomized Controlled Trial

Background: The number of people with dementia is increasing, with huge challenges for society and health-care systems. There are no disease-modifying therapies available. There is, therefore, an urgent need to identify strategies to reduce the risk of developing dementia. Anthocyanins are a class o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khalifa, Khadija, Bergland, Anne Katrine, Soennesyn, Hogne, Oppedal, Ketil, Oesterhus, Ragnhild, Dalen, Ingvild, Larsen, Alf Inge, Fladby, Tormod, Brooker, Helen, Wesnes, Keith A., Ballard, Clive, Aarsland, Dag
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492209/ https://www.ncbi.nlm.nih.gov/pubmed/32982933 http://dx.doi.org/10.3389/fneur.2020.00916

Ejemplares similares

Effects of Anthocyanin Supplementation on Serum Lipids, Glucose, Markers of Inflammation and Cognition in Adults With Increased Risk of Dementia – A Pilot Study
por: Bergland, Anne Katrine, et al.
Publicado: (2019)

Corrigendum: Effects of Anthocyanin Supplementation on Serum Lipids, Glucose, Markers of Inflammation and Cognition in Adults With Increased Risk of Dementia – A Pilot Study
por: Bergland, Anne Katrine, et al.
Publicado: (2021)

Persistence and Prognostic Implications of Orthostatic Hypotension in Older Individuals with Mild-to-Moderate Dementia
por: Soennesyn, Hogne, et al.
Publicado: (2014)

Cognitive decline in dementia with Lewy bodies: a 5-year prospective cohort study
por: Rongve, A, et al.
Publicado: (2016)

Relationship between Orthostatic Hypotension and White Matter Hyperintensity Load in Older Patients with Mild Dementia
por: Soennesyn, Hogne, et al.
Publicado: (2012)

White Matter Hyperintensities and the Course of Depressive Symptoms in Elderly People with Mild Dementia
por: Soennesyn, Hogne, et al.
Publicado: (2012)

FLAME: A computerized neuropsychological composite for trials in early dementia
por: Brooker, Helen, et al.
Publicado: (2020)

Body mass index, performance on activities of daily living and cognition: analysis in two different populations
por: Borda, Miguel Germán, et al.
Publicado: (2021)

Body mass index trajectories and associations with cognitive decline in people with Lewy body dementia and Alzheimer's disease
por: Borda, Miguel G., et al.
Publicado: (2022)

Classifying Dementia Using Local Binary Patterns from Different Regions in Magnetic Resonance Images
por: Oppedal, Ketil, et al.
Publicado: (2015)

Correlates of Subjective and Mild Cognitive Impairment: Depressive Symptoms and CSF Biomarkers
por: Grambaite, Ramune, et al.
Publicado: (2013)

Cognitive Deficits in Chronic Stroke Patients: Neuropsychological Assessment, Depression, and Self-Reports
por: Nakling, Arne E., et al.
Publicado: (2017)

Psychiatric and neuropsychiatric syndromes and COVID-19
por: Velayudhan, Latha, et al.
Publicado: (2020)

Mental health of people living with dementia in care homes during COVID-19 pandemic
por: Velayudhan, Latha, et al.
Publicado: (2020)

Factors associated with functional loss among community-dwelling Mexican older adults
por: Castellanos-Perilla, Nicolás, et al.
Publicado: (2020)

Genetic risk for Alzheimer's disease, cognition, and mild behavioral impairment in healthy older adults
por: Creese, Byron, et al.
Publicado: (2021)

Late‐life onset psychotic symptoms and incident cognitive impairment in people without dementia: Modification by genetic risk for Alzheimer's disease
por: Creese, Byron, et al.
Publicado: (2023)

Screening for Alzheimer’s Disease: Cognitive Impairment in Self-Referred and Memory Clinic-Referred Patients
por: Kirsebom, Bjørn-Eivind, et al.
Publicado: (2017)

White matter integrity and cognition in Parkinson's disease: a cross-sectional study
por: Auning, Eirik, et al.
Publicado: (2014)

Cerebrospinal Fluid Levels of sAPPα and sAPPβ in Lewy Body and Alzheimer's Disease: Clinical and Neurochemical Correlates
por: Mulugeta, Ezra, et al.
Publicado: (2011)

Hippocampal subfield atrophy in relation to cerebrospinal fluid biomarkers and cognition in early Parkinson’s disease: a cross-sectional study
por: Stav, Ane Løvli, et al.
Publicado: (2016)

Specific neuropsychiatric symptoms are associated with functional decline trajectories in Alzheimer’s disease and Lewy body dementia: a five-year follow-up study
por: Borda, Miguel Germán, et al.
Publicado: (2023)

Association Between Amygdala Volume and Trajectories of Neuropsychiatric Symptoms in Alzheimer's Disease and Dementia With Lewy Bodies
por: Jaramillo-Jimenez, Alberto, et al.
Publicado: (2021)

Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial
por: Husebo, Bettina S, et al.
Publicado: (2011)

Clinical trials in dementia with Lewy bodies: the evolving concept of co-pathologies, patient selection and biomarkers
por: Gibson, Lucy L., et al.
Publicado: (2023)

In Brief Neuropsychological Assessment, Amnestic Mild Cognitive Impairment (MCI) Is associated with Cerebrospinal Fluid Biomarkers for Cognitive Decline in Contrast to the Prevailing NIA-AA MCI Criterion
por: Hessen, Erik, et al.
Publicado: (2019)

Cerebrospinal fluid markers for synaptic function and Alzheimer type changes in late life depression
por: Siafarikas, Nikias, et al.
Publicado: (2021)

Author Correction: Cerebrospinal fluid markers for synaptic function and Alzheimer type changes in late life depression
por: Siafarikas, Nikias, et al.
Publicado: (2022)

Examining the association between genetic liability for schizophrenia and psychotic symptoms in Alzheimer’s disease
por: Creese, Byron, et al.
Publicado: (2019)

Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson's disease with dementia: a prospective study
por: Stubendorff, Kajsa, et al.
Publicado: (2014)

Antipsychotic use in dementia: the relationship between neuropsychiatric symptom profiles and adverse outcomes
por: Mueller, Christoph, et al.
Publicado: (2020)

Implementing Remote Memory Clinics to Enhance Clinical Care During and After COVID-19
por: Owens, Andrew P., et al.
Publicado: (2020)

International relevance of two measures of awareness of age-related change (AARC)
por: Sabatini, Serena, et al.
Publicado: (2020)

Efficacy and Safety of Analgesic Treatment for Depression in People with Advanced Dementia: Randomised, Multicentre, Double-Blind, Placebo-Controlled Trial (DEP.PAIN.DEM)
por: Erdal, Ane, et al.
Publicado: (2018)

Association of Klotho Protein Levels and KL-VS Heterozygosity With Alzheimer Disease and Amyloid and Tau Burden
por: Grøntvedt, Gøril Rolfseng, et al.
Publicado: (2022)

Cerebrospinal fluid neurogranin/β-site APP-cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer's disease
por: Kirsebom, Bjørn-Eivind, et al.
Publicado: (2018)

Neuropsychological Profiles in Mild Cognitive Impairment due to Alzheimer’s and Parkinson’s Diseases
por: Hessen, Erik, et al.
Publicado: (2016)

Optimised Anaesthesia to Reduce Post Operative Cognitive Decline (POCD) in Older Patients Undergoing Elective Surgery, a Randomised Controlled Trial
por: Ballard, Clive, et al.
Publicado: (2012)

Correction: Optimised Anaesthesia to Reduce Post Operative Cognitive Decline (POCD) in Older Patients Undergoing Elective Surgery, a Randomised Controlled Trial
por: Ballard, Clive, et al.
Publicado: (2012)

Correction: Optimised Anaesthesia to Reduce Post Operative Cognitive Decline (POCD) in Older Patients Undergoing Elective Surgery, a Randomised Controlled Trial
por: Ballard, Clive, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_93s12tfb99fb79cbqkq10ougru